毕赤酵母表达gp96-scFv抗体及生物活性测定

旨在利用毕赤酵母分泌表达gp96-scFv抗体,纯化后得到能特异性结合gp96抗原的小分子抗体片段(scFv)。根据gp96-scFv抗体基因序列,合成gp96-scFv抗体基因序列,将gp96-scFv抗体序列克隆到毕赤酵母表达质粒pPICZα-A,线性化的重组表达载体电转化到毕赤酵母X33,甲醇诱导目的蛋白表达,通过亲和层析法纯化目的蛋白,并以SDS-PAGE和Western blotting进行鉴定。通过Western blotting、Immunofluorescence、ELISA、FACS方法对gp96-scFv抗体的生物活性进行了检测。结果成功地构建了分泌表达抗gp96蛋白scFv抗体的毕赤酵母菌,每升毕赤酵母菌培养上清经纯化可获约50 mg gp96-scFv抗体,所获抗体其分子量大约为15 kDa,具有与gp96抗原特异性结合的活性。本研究通过毕赤酵母菌成功表达了gp96-scFv抗体,生物活性Western blotting、Immunofluorescence、ELISA、FACS分析表明该抗体能特异性结合gp96。     

Placental Transfer of a Fully Human IgG2 Monoclonal Antibody in the Cynomolgus Monkey,Rat, and Rabbit: A Comparative Assessment from during Organogenesis to Late Gestation

Understanding species differences in the placental transfer of monoclonal antibodies is important to inform species selection for nonclinical safety assessment, interpret embryo‐fetal changes observed in these studies, and extrapolate their human relevance. Data presented here for a fully human immunoglobulin G2 monoclonal antibody (IgG2X) revealed that, during organogenesis, in both the cynomolgus monkey (gestation day 35 [gd35]) and the rat (gd10) the extent of IgG2X placental transfer (approximately 0.5% maternal plasma concentration, MPC) was similar to the limited published human data for endogenous IgG. At this early gestational stage, IgG2X placental transfer was approximately 6‐fold higher in the rabbit (gd10). By the end of organogenesis, rat embryonic plasma concentrations (gd16) exceeded those in the cynomolgus monkey (gd50) by approximately 3‐fold. These data suggest that relative to the cynomolgus monkey, the rabbit (and to a lesser extent the rat) may overestimate potential harmful effects to the human embryo during this critical period of development. Beyond organogenesis, fetal IgG2X plasma concentrations increased approximately 10‐fold early in the second trimester (gd50–70) in the cynomolgus monkey and remained relatively unchanged thereafter (at approximately 5% MPC). Late gestational assessment was precluded in rabbits due to immunogenicity, but in rats, fetal IgG2X plasma concentrations increased more than 6‐fold from gd16 to gd21 (reaching approximately 15% MPC). In rats, maternal exposure consistent with that achieved by ICH S6(R1) high‐dose selection criteria resulted in embryonic plasma concentrations, reaching pharmacologically relevant levels during organogenesis. Furthermore, dose proportional exposure in both mothers and embryos indicated that this was unlikely to occur at the lower therapeutic dose levels used in humans     

Towards defining biomarkers indicating resistances to targeted therapies

An impressive, but often short objective response was obtained in many tumor patients treated with different targeted therapies, but most of the patients develop resistances against these drugs. So far, a number of distinct mechanisms leading to intrinsic as well as acquired resistances have been identified in tumors of distinct origin. These can arise from genetic alterations, like mutations, truncations, and amplifications or due to deregulated expression of various proteins and signal transduction pathways, but also from cellular heterogeneity within tumors after an initial response. Therefore, biomarkers are urgently needed for cancer prognosis and personalized cancer medicine. The application of “ome”-based technologies including cancer (epi)genomics, next generation sequencing, cDNA microarrays and proteomics might led to the predictive or prognostic stratification of patients to categorize resistance mechanisms and to postulate combinations of treatment strategies. This review discusses the implementation of proteome-based analysis to identify markers of pathway (in)activation in tumors and the resistance mechanisms, which represent major clinical problems as a tool to optimize individually tailored therapies based on targeted drugs. This article is part of a Special Issue entitled: Biomarkers: A Proteomic Challenge.     

Engineered Fc based antibody domains and fragments as novel scaffolds

Therapeutic monoclonal antibodies (mAbs) have been successful for the therapy of a number of diseases mostly cancer and immune disorders. However, the vast majority of mAbs approved for clinical use are full size, typically in IgG1 format. These mAbs may exhibit relatively poor tissue penetration and restricted epitope access due to their large size. A promising solution to this fundamental limitation is the engineering of smaller scaffolds based on the IgG1 Fc region. These scaffolds can be used for the generation of libraries of mutants from which high-affinity binders can be selected. Comprised of the CH2 and CH3 domains, the Fc region is important not only for the antibody effector function but also for its long half-life. This review focuses on engineered Fc based antibody fragments and domains including native (dimeric) Fc and monomeric Fc as well as CH2 and monomeric CH3, and their use as novel scaffolds and binders. The Fc based binders are promising candidate therapeutics with optimized half-life, enhanced tissue penetration and access to sterically restricted binding sites resulting in an increased therapeutic efficacy. This article is part of a Special Issue entitled: Recent advances in molecular engineering of antibody.     

抗IFITM1 单克隆抗体的制备及检测

目的：制备抗干扰素诱导的跨膜蛋白-1(interferon-induced transmembrane protein 1, IFITM1)的单克隆抗体,为检测IFITM1 及进一步研究其在结肠肿瘤发生过程中的作用提供实验基础。方法：以结肠癌患者的癌组织为材料,提取总RNA,以RT-PCR扩 增得到IFITM1 cDNA 序列,经ECoRⅠ和HindⅢ双酶切后,克隆入pGEX-4T-3 进行原核表达并纯化得IFITM1-GST;以该融合蛋 白免疫BALB/c 小鼠,淋巴细胞杂交瘤法制备单克隆抗体;采用ELISA、Western-blot及免疫组织化学法以制备的抗体检测结肠癌 患者结肠癌组织中的IFITM1。结果：成功构建了IFITM1 原核表达载体,获得了IFITM1-GST 重组蛋白;制备得到了1 株抗 IFITM1 单克隆抗体,腹水ELISA 效价为1:30000,抗体亚类为IgG1,可用于ELISA、Western-blot及免疫组织化学法检测结肠癌患 者结肠癌组织中的IFITM1。结论：获得了1 株可用于ELISA、Western-blot及免疫组织化学法的抗IFITM1 单克隆抗体2F-1,为进 一步研究IFITM1在结肠肿瘤发生过程中的作用提供了实验基础。     

抗 Trx 单克隆抗体用于血吸虫病诊断的研究 *

摘要 目的： 建立双抗体夹心 ELISA 法检测日本血吸虫硫氧还蛋白 （Thioredoxin,Trx ）。方法： 用重组日本血吸虫 Trx （rTrx ） 蛋白免 疫 BALB/c 小鼠, 筛选高滴度、 高特异性的单克隆抗体建立双抗体夹心 ELISA 法。通过检测日本血吸虫排泄 - 分泌物 （ excretorysecretions,ES ） 与 rTrx 的浓度评价该方法的敏感性; 通过对健康人血清的检测确定其特异性; 通过对布氏姜片吸虫病、 华支睾吸虫 病、 卫氏并殖吸虫病、 囊虫病患者血清进行交叉反应试验, 评价该方法的特异性。 结果： 获得 2 株稳定分泌抗 rTrx 蛋白单克隆抗体 的杂交瘤细胞株, 命名为 McTrx1 和 McTrx2。以 McTrx1 为包被抗体, HRP-McTrx2 为酶标抗体, 建立的双抗体夹心 ELISA 可检 测出 ES 的最低浓度为 4.8 μg/ml, 检测出 rTrx 的最低浓度为 1.2 μg/ml。 该方法的特异性为 96%。 结论： 以抗 rTrx 蛋白单克隆抗体 McTrx1 与 McTrx2 为基础建立的双抗体夹心 ELISA 法具有较高的特异性。     

Characterization of VRC01, a potent and broadly neutralizing anti‐HIV mAb,produced in transiently and stably transformed tobacco

The proposed clinical trial in Africa of VRC01, a potent broadly neutralizing antibody (bNAb) capable of neutralizing 91% of known HIV‐1 isolates, raises concerns about testing a treatment which will be too expensive to be accessible by the most important target population, the poor in under‐developed regions such as sub‐Saharan Africa. Here, we report the expression of VRC01 in plants as an economic alternative to conventional mammalian‐cell‐based production platforms. The heavy and light chain genes of VRC01 were cloned onto a single vector, pTRAk.2, which was transformed into Nicotiana benthamiana or Nicotiana tabacum using transient and stable expression production systems respectively. VRC01 has been successfully expressed transiently in plants with expression level of approximately 80 mg antibody/kg; stable transgenic lines expressing up to 100 mg antibody/kg were also obtained. Plant‐produced VRC01 from both systems showed a largely homogeneous N‐glycosylation profile with a single dominant glycoform. The binding kinetics to gp120 IIIB (approximately 1 nm ), neutralization of HIV‐1 BaL or a panel of 10 VRC01‐sensitive HIV‐1 Env pseudoviruses of VRC01 produced in transient and stable plants were also consistent with VRC01 from HEK cells.     

Structural and functional characterization of an anti‐West Nile virus monoclonal antibody and its single‐chain variant produced in glycoengineered plants

Previously, our group engineered a plant‐derived monoclonal antibody (MAb pE16) that efficiently treated West Nile virus (WNV) infection in mice. In this study, we developed a pE16 variant consisting of a single‐chain variable fragment (scFv) fused to the heavy chain constant domains (C_H) of human IgG (pE16scFv‐C_H). pE16 and pE16scFv‐C_H were expressed and assembled efficiently in Nicotiana benthamiana ?XF plants, a glycosylation mutant lacking plant‐specific N‐glycan residues. Glycan analysis revealed that ?XF plant‐derived pE16scFv‐C_H (?XFpE16scFv‐C_H) and pE16 (?XFpE16) both displayed a mammalian glycosylation profile. ?XFpE16 and ?XFpE16scFv‐C_H demonstrated equivalent antigen‐binding affinity and kinetics, and slightly enhanced neutralization of WNV in vitro compared with the parent mammalian cell‐produced E16 (mE16). A single dose of ?XFpE16 or ?XFpE16scFv‐C_H protected mice against WNV‐induced mortality even 4 days after infection at equivalent rates as mE16. This study provides a detailed tandem comparison of the expression, structure and function of a therapeutic MAb and its single‐chain variant produced in glycoengineered plants. Moreover, it demonstrates the development of anti‐WNV MAb therapeutic variants that are equivalent in efficacy to pE16, simpler to produce, and likely safer to use as therapeutics due to their mammalian N‐glycosylation. This platform may lead to a more robust and cost‐effective production of antibody‐based therapeutics against WNV infection and other infectious, inflammatory or neoplastic diseases.     

The antibody response against MART‐1 differs in patients with melanoma‐associated leucoderma and vitiligo

Patients with melanoma may develop skin depigmentation spontaneously or following therapy, referred to as melanoma‐associated leucoderma (MAL). As clinical presentation of MAL may precede primary/metastatic melanoma detection, recognition of MAL is important to prevent its misdiagnosis as vitiligo and the subsequent application of immunosuppressive treatment. To reveal the immunity involved in MAL development, we investigated the presence of antibody and T‐cell immune responses directed against the melanocyte‐differentiation‐antigens MART‐1 (Melan‐A), tyrosinase and gp100 in patients with MAL, as compared to patients with vitiligo. Autoantibodies to gp100 and tyrosinase were commonly found in both diseases. Interestingly, MART‐1 antibodies were only present in patients with MAL. Melanocyte antigen‐specific T cells were found in all patients, with relatively more specific T cells in patients with active vitiligo. Although MAL and vitiligo may appear clinically similar, our results indicate that the humoral immune responses against MART‐1 differ between these diseases, which can help to differentiate MAL from vitiligo.     

ICR 小鼠自然感染小鼠肝炎病毒后抗原抗体的变化

目的：了解小鼠肝炎病毒（ MHV）污染的设施内,ICR小鼠自然感染后MHV抗原抗体存在情况。方法选择50只ICR小鼠,通过更换“脏垫料”的方式进行饲养,分别在实验第2,4,8,14,21,28,35,42,56和84天各剖杀动物5只,采集血清、盲肠内容物、粪便、肝脏以及肺脏检测抗原抗体分布情况。结果实验开始第2天,肺脏中检出小鼠肝炎病毒,检出率为20％（1/5）,第4天开始,肝脏、肺部、盲肠以及粪便中均可检出小鼠肝炎病毒;84天后,肺脏、盲肠、粪便和肝脏阳性检出率降为0。实验第8天,血清中抗体检出阳性,阳性率为100％（5/5）,直至第84天实验结束,抗体阳性率仍维持在100％（5/5）。结论血清学方法可作为日常监督主要诊断方法,而抗原检测方法只能应用于早期诊断。